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Background: 50% to 85% of the patients infected by hep-
titis C virus will develop a chronic infection, 20% of them
ill suffer from cirrhosis and 1% to 4% will develop hepa-
ocellular carcinoma. Morfologic and hemodynamic changes
hich occur in the liver and in the portal system can be
valuated by Doppler ultrasonography at an early stage and
n a non-invasive way.The main purpose of this paper was
o study alterations detected by ultrasonography examina-
ions in hepatitis C patients assisted at Fundac¸ão de Medicina
ropical do Amazonas.
Methods: In an 8-month period, 50 patients anti-HCV pos-
tive whose ages ranged from 18 to 69 were submitted to
oppler ultrasonography examinations.
Results: Most of the patients were males (74%) at an
verage age of 47,1. Morfologic alterations were detected,
uch as increase of the volume of the liver (12%) mainly
n the left liver lobe, increase of liver ecogenicity (24%),
splenomegaly (14%) and increase of ecogenicity and gall-
ladder wall thicknen (4%).
Conclusion: Hemodynamic alterations were noticed,
ostly a reduction on the portal vein velocity (26%), alter-
tions on the congestion index (12%), on the vascular hepatic
ndex (16%) and impedance of hepatic and splanchinic arte-
ial index.
oi:10.1016/j.ijid.2010.02.2013
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etection of acute HCV infection among different risk
roups
. Gatserelia ∗, L. Sharvadze, M. Karchava, N. Dvali, L.
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Background: To investigate acute HCV infection from the
ery ﬁrst days of the infection among blood donors, inject-
ng drug users (IDUs), health care workers and persons who
ad ﬁrst life time sexual intercourse with the chronic HCV
nfected persons in orders to asses clinical laboratory vari-
nts of infection, viral replication kinetic, disease outcome.Methods: Study was performed among ELISA negative
ersons in four groups: 7500 blood donors, 3200 IDUs, 70
xposed health care workers and 45 persons who had ﬁrst
ife time sexual intercourse with the chronic HCV infected
m
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ersons. All groups were investigated on HCV RNA by Real
ime PCR (COBAS TaqMan Roche) using pool method and
enotyped by line probe assay (Innolipa, Versant, Bayer)
ccording to the manufacturer’s instructions. The results
ere analyzed by age, sex, duration of infection, modes of
ransmission and other variables.
Results: Total of 21 patients with acute HCV infection
ere identiﬁed: 7 from blood donors, 9 from IDUs, 1 from
ealth care workers and 4 from persons who had ﬁrst
ife time sexual intercourse with the chronic HCV infected
atients. All HCV RNA positive persons revealed within the
tudy were followed on viral load dynamic at detection
oment and at 2, 4 and 8 weeks and after 3 and 6 months
rom their possible exposure. Among them: 5 were symp-
omatic and 16 asymptomatic. Among 21 subjects: 10 had
enotype - 1b, 5 - 2a/2c and 6 - 3a. Out of 21 patients 7
leared the virus (5 were symptomatic: 1 - genotype 1b, 2
genotype 2a/2c, 2 - genotype 3a, and 2 asymptomatic:
- genotype 1b, 1 - genotype 3a), while 14 developed
hronic infection. In all patients viremia increased rapidly
nd reached a peak by week 4. After week 10 the viremia
apidly decreased. It became either undetectable by weeks
6-18 (viral clea rance), or virus was not eliminated (chronic
nfection).
Conclusion: We found that HCV viral clearance was cor-
elated with high viral titers, symptomatic form of disease
nd sexually transmitted HCV infection in female subjects.
tudy revealed no correlations between viral genotype and
iral clearance rates.
oi:10.1016/j.ijid.2010.02.2014
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aseline biochemical levels
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Background: Adefovir dipivoxil (ADV) has shown efﬁcacy
nd safety in a broad range of populations with chronic
epatitis B over 48 to 96 weeks. This study reports the
6-week long-term efﬁcacy data with ADV treatment in
ucleoside-naive HBeAg-positive chronic hepatitis B patients
ith various baseline biochemical levels.
Methods: Ninety-eight HBeAg-positive patients who had
ever received nucleoside treatment received 96-week ADV
0mg/d therapy. All patients had serum level of HBV load
ver 105 copies/ml and increased serum alanine aminotrans-
erase (ALT) level. Based on serum ALT levels at baseline,
ll patients were divided into two groups, A (48 patients
ith serum ALT level less than 200U/L) and B (50 patients
ith ALT level more than 200 U/L). Serum HBV load was
easured with quantitative real-time-PCR. ALT activity,
BeAg, anti-HBeantibodies, HBV-DNA level in serum were
valuated at baseline, week 12, 24, 48 and 96 during ther-
py.
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Results: After 24 weeks of therapy, mean reduction of
HBV-DNA level, the percentage of patients with HBV-DNA
lower than 5 log10 copies/ml and the percentage of patients
with HBV-DNA level decrease of more than 2 log10 copies/ml
in group B were signiﬁcantly higher than those in group A
(P < 0.05, respectively). At the end of 24, 48 and 96 weeks,
the patients in group B had higher rates of undetectable
serum HBV-DNA levels and ALT normalization than those in
group A (46% vs 25%, 74% vs 54.2%, 88% vs 70.8%; 52% vs
31.3%, 66% vs 43.8%, 82% vs 62.5%; P < 0.05, respectively).
HBeAg seroconversion rate was signiﬁcant hihger in group B
than those in group A (48% vs 27.1%, P < 0.05). There was no
evidence of adverse effect in patients treated for up to 96
weeks.
Conclusion: Adefovir dipivoxil is an effective treatment
option for nucleoside-naive patients with HBeAg-positive
chronic hepatitis B, especially for those with high serum ALT
levels at baseline. Adefovir dipivoxil treatment through 96
weeks was well tolerated and resulted in continued beneﬁt
for patients with HBeAg-positive chronic hepatitis B.
doi:10.1016/j.ijid.2010.02.2015
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Background: To investigate peripheral T-lymphocyte sub-
population proﬁle and its correlation with HBV precore
region 1896 mutation in chronic HBV-infected (CHI) individ-
uals with normal liver function tests.
Methods: HBV precore region 1896 mutation and distri-
bution of T-lymphocyte subpopulations in peripheral blood
were measured in CHI individuals with normal liver func-
tion tests. HBV markers were detected with ELISA. Serum
HBV DNA load was assessed with quantitative real-time
polymerase chain reaction. The results of peripheral T-cell
subsets were compared among groups based on HBV pre-
core region 1896 mutation status, HBeAg, age, sex and the
quantities of HBV DNA.
Results: CHI individuals with normal liver function tests
had signiﬁcantly decreased CD4+ cells and CD4+/CD8+ ratio,
and increased CD8+ cells compared with unifected controls,
all with P < 0.01. Comparing with HBV precore region non-
mutation group, the patients with precore mutation had
signiﬁcant decreased CD4+ cells and CD4+/CD8+ ratio and
increased CD8+ cells. Univariate analysis showed a simi-
lar pattern of these parameters was signiﬁcantly associated
with presence of serum HBeAg expression and high viral
load, all with P < 0.05 or 0.01. The presence of HBeAg
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xpression carried by the HBV precore region mutation
ositive group were not signiﬁcant different than those
bserved in HBV precore region mutation negative group.
here is a signiﬁcant difference in the quantities of HBV
NA between the HBV precore region mutation positive
roup and negative group. No obvious differences of T-
ell parameters and presence of precore mutation were
bserved among various age groups and sex groups, all with
> 0.05.
Conclusion: T-lymphocyte impaired balance was signiﬁ-
antly associated with HBV precore region mutation in CHI
ndividuals with normal liver function tests. Which with
BeAg expression and the HBV DNA replication affect each
ther and co-result in lower T-cell immune function and
hronic infection persistent status.
oi:10.1016/j.ijid.2010.02.2016
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Background: Brazil has been classiﬁed as high endemic
ountry and HAV vaccine is not implemented in the routine
mmunization calendar. The objectives were to estimate the
revalence of hepatitis A among children and adolescents
y Brazilian regions and household/contextual risk factors
ssociation. This population-based survey was conducted
etween 2004 and 2009. It was a Ministry of Health and
AHO initiative with the Universities and Public laboratories
ocated in the State capitals.
Methods: A stratiﬁed multistage cluster sampling tech-
ique with probability proportional to size was used to
elect around 6400 individuals aged between 5 and 19
ears residents of the State capitals and the Federal Dis-
rict. The sample was stratiﬁed according to age (5—9
nd 10- to 19-years-old) within each region. Individual-
nd household-level data were collected by home inter-
